<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626886</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-003</org_study_id>
    <nct_id>NCT00626886</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy</brief_title>
  <official_title>A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRxÂ® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the CollaRx Bupivacaine implant is safe and&#xD;
      effective in reducing the amount of narcotic pain medication needed to control pain during&#xD;
      the first 24 hours after herniorrhaphy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inguinal herniorrhaphy is a common surgery; and common surgical methods used include&#xD;
      laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly&#xD;
      reduce the risk of hernia recurrence regardless of the method used for its placement.&#xD;
      Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain&#xD;
      considerable medical challenges.&#xD;
&#xD;
      Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile.&#xD;
      Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin&#xD;
      flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When&#xD;
      inserted into a surgical site, the collagen breaks down and bupivacaine is released at the&#xD;
      site but very little is absorbed into the blood stream. The high levels of bupivacaine at the&#xD;
      surgical site may result in less pain for several days after surgery.&#xD;
&#xD;
      This study will compare the amount of narcotic pain medication required after surgery in&#xD;
      patients who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2008</start_date>
  <completion_date type="Actual">January 29, 2009</completion_date>
  <primary_completion_date type="Actual">January 29, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours</measure>
    <time_frame>0 to 24 hours postoperatively</time_frame>
    <description>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours</measure>
    <time_frame>0 to 48 hours postoperatively</time_frame>
    <description>Number count. Higher score means worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours</measure>
    <time_frame>0 to 72 hours postoperatively</time_frame>
    <description>Number count - higher score means worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)</measure>
    <time_frame>1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0</time_frame>
    <description>Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting &amp; Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale</measure>
    <time_frame>At 72 hours after time 0</time_frame>
    <description>For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain Intensity Scores Over Time</measure>
    <time_frame>At 1, 1.5, 2,3,4,5,6,24,48,72 Hours</time_frame>
    <description>For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Pain Intensity Scores Over Time - AT REST</measure>
    <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
    <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Pain Relief Scores Over Time - AT REST</measure>
    <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
    <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Pain Intensity Scores Over Time (After Cough)</measure>
    <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
    <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot; Higher Score means a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Pain Relief Scores Over Time (After Cough)</measure>
    <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
    <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo collagen sponge implanted during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Collagen Sponge</intervention_name>
    <description>collagen; Bupivacaine hydrocholoride</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CollaRx Bupivacaine Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo collagen sponge</intervention_name>
    <description>collagen</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has body mass index (BMI) &gt; 19 and &lt; 40 kg/m2.&#xD;
&#xD;
          -  Has a planned unilateral inguinal herniorrhaphy (open mesh, tension free technique) to&#xD;
             be performed according to standard surgical technique under general anesthesia.&#xD;
&#xD;
          -  Has a risk classification of I, II or III according to the ASA.&#xD;
&#xD;
          -  Is free of other physical or mental conditions that, in the opinion of the&#xD;
             Investigator, may confound the quantification of postoperative pain after&#xD;
             herniorrhaphy.&#xD;
&#xD;
          -  Has the ability and willingness to comply with the study procedures and the use of the&#xD;
             pain scales.&#xD;
&#xD;
          -  Is willing to use only permitted medications and anesthetics throughout the study.&#xD;
&#xD;
          -  Is willing to use opioid rescue analgesia for moderate to severe incisional pain only.&#xD;
&#xD;
          -  Must voluntarily sign and date an informed consent form (ICF) that is approved by an&#xD;
             Institutional Review Board (IRB) before the conduct of any study specific procedures.&#xD;
&#xD;
          -  Must be able to fluently speak and understand English and be able to provide&#xD;
             meaningful written informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known hypersensitivity to amide local anesthetics, opioids, bovine products or&#xD;
             inactive ingredients of the test article.&#xD;
&#xD;
          -  Is scheduled for bilateral inguinal herniorrhaphy.&#xD;
&#xD;
          -  Has undergone a prior herniorrhaphy on the side that is currently scheduled for&#xD;
             repair.&#xD;
&#xD;
          -  Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.&#xD;
&#xD;
          -  Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate&#xD;
             cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and&#xD;
             grapefruit juice).&#xD;
&#xD;
          -  Has used long acting analgesics within 24 hours of surgery. Short acting analgesics&#xD;
             such as acetaminophen may be used on the day of surgery&#xD;
&#xD;
          -  Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a&#xD;
             dose of â¤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on&#xD;
             a stable dose regimen for â¥ 30 days before Screening.&#xD;
&#xD;
          -  Has undergone major surgery within 3 months of the scheduled herniorrhaphy.&#xD;
&#xD;
          -  Has known or suspected history of alcohol or drug abuse or misuse within 3 years of&#xD;
             Screening or evidence of tolerance or physical dependency on opioid analgesics or&#xD;
             sedative-hypnotic medications.&#xD;
&#xD;
          -  Has used opioids or tramadol on an extended daily basis (&gt; 7 days) before surgery.&#xD;
             Patients who, in the Investigator's opinion, are developing opioid tolerance are to be&#xD;
             excluded.&#xD;
&#xD;
          -  Has impaired liver function, aspartate aminotransferase (AST)/alanine aminotransferase&#xD;
             (ALT)/bilirubin â¥ 3.0 times the upper limit of normal (ULN), active hepatic disease,&#xD;
             evidence of clinically significant liver disease or another condition (eg, alcoholism,&#xD;
             cirrhosis or hepatitis) that may suggest the potential for an increased susceptibility&#xD;
             to hepatic toxicity with exposure to test article.&#xD;
&#xD;
          -  Has any clinically significant unstable cardiac, neurological, immunological, renal or&#xD;
             hematological disease or any other condition that, in the opinion of the Investigator,&#xD;
             could compromise the patient's welfare, ability to communicate with the study staff or&#xD;
             otherwise contraindicate study participation.&#xD;
&#xD;
          -  Is judged by the Investigator to be at risk for infection or slow wound healing.&#xD;
&#xD;
          -  Has a chronic painful condition that might confound the assessment of pain associated&#xD;
             with the herniorrhaphy.&#xD;
&#xD;
          -  Routinely uses pain medication that, in the opinion of the Investigator, could&#xD;
             confound the pain assessments during the study.&#xD;
&#xD;
          -  Has been treated with agents that could affect the analgesic response (such as central&#xD;
             alpha agents, neuroleptic agents and other antipsychotic agents) within 2 weeks of&#xD;
             surgery.&#xD;
&#xD;
          -  Has been treated with monoamine oxidase inhibitors (MAOIs) within 10 days of surgery.&#xD;
&#xD;
          -  Has been treated with systemic corticosteroids within 7 days of surgery (inhaled and&#xD;
             topical corticosteroids are allowed).&#xD;
&#xD;
          -  Has participated in a clinical trial within 30 days of surgery.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Prior</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dovepress.com/articles.php?article_id=10236</url>
    <description>Clinical evaluation of a Bupivacaine-Collagen Implant (XaraCollÂ®) for postoperative analgesia from two multicenter, randomized, double-blind, placebo-controlled pilot studies</description>
  </link>
  <results_reference>
    <citation>Cusack SL, Jaros M, Kuss M, Minkowitz HS, Winkle P, Hemsen L. Clinical evaluation of XaraColl(Â®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studies. J Pain Res. 2012;5:217-25. doi: 10.2147/JPR.S33453. Epub 2012 Jun 27.</citation>
    <PMID>22792007</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>January 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herniorrhaphy</keyword>
  <keyword>Inguinal Hernia Repair</keyword>
  <keyword>Postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Investigative medical sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
        </group>
        <group group_id="P2">
          <title>Placebo Collagen Sponge</title>
          <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat</population>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
        </group>
        <group group_id="B2">
          <title>Placebo Collagen Sponge</title>
          <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.1" spread="13.08"/>
                    <measurement group_id="B2" value="52.6" spread="15.71"/>
                    <measurement group_id="B3" value="49.6" spread="14.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours</title>
        <description>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome</description>
        <time_frame>0 to 24 hours postoperatively</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours</title>
          <description>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome</description>
          <population>intent-to-treat</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.48" spread="12.65"/>
                    <measurement group_id="O2" value="24.60" spread="15.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours</title>
        <description>Number count. Higher score means worse outcome</description>
        <time_frame>0 to 48 hours postoperatively</time_frame>
        <population>In the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours</title>
          <description>Number count. Higher score means worse outcome</description>
          <population>In the ITT population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.60" spread="19.880"/>
                    <measurement group_id="O2" value="36.50" spread="25.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours</title>
        <description>Number count - higher score means worse outcome</description>
        <time_frame>0 to 72 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours</title>
          <description>Number count - higher score means worse outcome</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.20" spread="29.296"/>
                    <measurement group_id="O2" value="44.89" spread="35.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)</title>
        <description>Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting &amp; Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.</description>
        <time_frame>1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0</time_frame>
        <population>In the ITT population using the mWOCF method of imputation, the differences in the mean summed pain intensity (SPI) VAS at-rest score</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)</title>
          <description>Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting &amp; Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.</description>
          <population>In the ITT population using the mWOCF method of imputation, the differences in the mean summed pain intensity (SPI) VAS at-rest score</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 to 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.8" spread="283.84"/>
                    <measurement group_id="O2" value="862.0" spread="573.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.0" spread="360.31"/>
                    <measurement group_id="O2" value="594.6" spread="580.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>49 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.5" spread="217.11"/>
                    <measurement group_id="O2" value="426.6" spread="488.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1060.3" spread="788.62"/>
                    <measurement group_id="O2" value="1883.3" spread="1585.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale</title>
        <description>For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent</description>
        <time_frame>At 72 hours after time 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale</title>
          <description>For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very good,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain Intensity Scores Over Time</title>
        <description>For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
        <time_frame>At 1, 1.5, 2,3,4,5,6,24,48,72 Hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain Intensity Scores Over Time</title>
          <description>For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
          <population>Intent-to-Treat Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="21.82"/>
                    <measurement group_id="O2" value="48.2" spread="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="15.37"/>
                    <measurement group_id="O2" value="52.9" spread="25.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="16.50"/>
                    <measurement group_id="O2" value="49.6" spread="27.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="13.45"/>
                    <measurement group_id="O2" value="45.6" spread="23.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="13.51"/>
                    <measurement group_id="O2" value="40.8" spread="27.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="15.25"/>
                    <measurement group_id="O2" value="40.8" spread="29.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="13.94"/>
                    <measurement group_id="O2" value="41.6" spread="28.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="20.52"/>
                    <measurement group_id="O2" value="29.3" spread="28.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="12.52"/>
                    <measurement group_id="O2" value="20.2" spread="21.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="7.63"/>
                    <measurement group_id="O2" value="15.3" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Pain Intensity Scores Over Time - AT REST</title>
        <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot;</description>
        <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Pain Intensity Scores Over Time - AT REST</title>
          <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot;</description>
          <population>Intent-to-Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.87"/>
                    <measurement group_id="O2" value="1.3" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.66"/>
                    <measurement group_id="O2" value="1.8" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.58"/>
                    <measurement group_id="O2" value="1.8" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.51"/>
                    <measurement group_id="O2" value="1.8" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.53"/>
                    <measurement group_id="O2" value="1.7" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.47"/>
                    <measurement group_id="O2" value="1.6" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.51"/>
                    <measurement group_id="O2" value="1.7" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.47"/>
                    <measurement group_id="O2" value="1.6" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.65"/>
                    <measurement group_id="O2" value="1.3" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.62"/>
                    <measurement group_id="O2" value="1.0" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.56"/>
                    <measurement group_id="O2" value="0.7" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Pain Relief Scores Over Time - AT REST</title>
        <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
        <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Pain Relief Scores Over Time - AT REST</title>
          <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
          <population>Intent-to-Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.20"/>
                    <measurement group_id="O2" value="1.6" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.76"/>
                    <measurement group_id="O2" value="1.6" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.83"/>
                    <measurement group_id="O2" value="1.5" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.00"/>
                    <measurement group_id="O2" value="1.6" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.81"/>
                    <measurement group_id="O2" value="2.0" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.83"/>
                    <measurement group_id="O2" value="2.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.93"/>
                    <measurement group_id="O2" value="2.0" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.99"/>
                    <measurement group_id="O2" value="2.1" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.9"/>
                    <measurement group_id="O2" value="2.4" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.93"/>
                    <measurement group_id="O2" value="2.8" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.93"/>
                    <measurement group_id="O2" value="3.0" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Pain Intensity Scores Over Time (After Cough)</title>
        <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot; Higher Score means a worse outcome</description>
        <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Pain Intensity Scores Over Time (After Cough)</title>
          <description>For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = &quot;none,&quot; 1 = &quot;mild,&quot; 2 = &quot;moderate&quot; and 3 = &quot;severe.&quot; Higher Score means a worse outcome</description>
          <population>Intent-to-Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.97"/>
                    <measurement group_id="O2" value="1.3" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.78"/>
                    <measurement group_id="O2" value="2.1" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.58"/>
                    <measurement group_id="O2" value="2.1" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.65"/>
                    <measurement group_id="O2" value="2.2" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.66"/>
                    <measurement group_id="O2" value="2.0" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.59"/>
                    <measurement group_id="O2" value="2.0" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.78"/>
                    <measurement group_id="O2" value="2.0" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.58"/>
                    <measurement group_id="O2" value="2.0" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.65"/>
                    <measurement group_id="O2" value="1.8" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.61"/>
                    <measurement group_id="O2" value="1.4" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.55"/>
                    <measurement group_id="O2" value="1.1" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Pain Relief Scores Over Time (After Cough)</title>
        <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
        <time_frame>At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
          </group>
          <group group_id="O2">
            <title>Placebo Collagen Sponge</title>
            <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Pain Relief Scores Over Time (After Cough)</title>
          <description>For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.</description>
          <population>Intent-to-Treat Population</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.20"/>
                    <measurement group_id="O2" value="1.6" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.90"/>
                    <measurement group_id="O2" value="1.3" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.87"/>
                    <measurement group_id="O2" value="1.4" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.92"/>
                    <measurement group_id="O2" value="1.2" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.78"/>
                    <measurement group_id="O2" value="1.7" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".2" spread="0.90"/>
                    <measurement group_id="O2" value="1.7" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.02"/>
                    <measurement group_id="O2" value="1.6" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.03"/>
                    <measurement group_id="O2" value="1.7" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.08"/>
                    <measurement group_id="O2" value="2.0" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.02"/>
                    <measurement group_id="O2" value="2.3" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.95"/>
                    <measurement group_id="O2" value="2.7" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Two, 5x5cm bupivacaine collagen sponges implanted during surgery&#xD;
Bupivacaine Collagen Sponge: collagen; Bupivacaine hydrocholoride</description>
        </group>
        <group group_id="E2">
          <title>Placebo Collagen Sponge</title>
          <description>Placebo collagen sponge implanted during surgery&#xD;
placebo collagen sponge: collagen</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management</name_or_title>
      <organization>Innocoll</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

